Wounds : a compendium of clinical research and practice · 2023
Leukocyte- and platelet-rich fibrin treatment of chronic lower extremity ulcer in a patient with systemic lupus erythematosus: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Chunyu, Zhang Jing, Wang Fen, Li Weili, Xu Qinqin, Shao Shiying
Аннотация
INTRODUCTION: Lower extremity ulcer is a severe complication in patients with autoimmune disease, and treatment is difficult and time-consuming. L-PRF has been widely used in mammalian regenerative medicine owing to its ease of use and low cost. However, few studies have been published on the application of L-PRF in autoimmune-associated ulcers.
CASE REPORT: This case report discusses a 26-year-old male patient with SLE who presented to the authors' institution with a chronic lower extremity ulcer of 8 months' duration. He received once-weekly L-PRF treatment along with standard wound care. After 15 treatments, the ulcer was completely epithelialized, with a healing rate of 3.8 cm2 per week.
CONCLUSIONS: This case report provides a promising therapeutic strategy for the treatment of autoimmune-associated ulcers. More robust data from case series and RCTs are required to further evaluate the clinical efficacy of L-PRF in refractory ulcers in patients with autoimmune disease.
CASE REPORT: This case report discusses a 26-year-old male patient with SLE who presented to the authors' institution with a chronic lower extremity ulcer of 8 months' duration. He received once-weekly L-PRF treatment along with standard wound care. After 15 treatments, the ulcer was completely epithelialized, with a healing rate of 3.8 cm2 per week.
CONCLUSIONS: This case report provides a promising therapeutic strategy for the treatment of autoimmune-associated ulcers. More robust data from case series and RCTs are required to further evaluate the clinical efficacy of L-PRF in refractory ulcers in patients with autoimmune disease.